GSK, Pfiz­er head in­to patent du­el in high-stakes RSV vac­cine war

A patent bat­tle is un­der­way be­tween GSK and Pfiz­er in the US, with the for­mer call­ing for a ju­ry tri­al over their re­spec­tive RSV vac­cines, both set for wide­spread launch in the fall.

In a fresh law­suit, GSK is al­leg­ing Pfiz­er in­fringed on four patents re­lat­ed to GSK’s Arexvy vac­cine, which locked in an FDA OK on May 3 in adults 60 years and over. Pfiz­er’s Abrys­vo was ap­proved on May 31.

A court doc­u­ment filed on Wednes­day at the Delaware Dis­trict Court shows the patent dis­pute re­volves around vac­cine com­po­si­tion and how they are pre­pared. Arexvy is de­signed to in­duce a re­sponse against RSVpreF3, while Abrys­vo tar­gets RSV pre F, ac­cord­ing to their re­spec­tive FDA la­bels.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER